MDLinxPfizer’s Diabetes Drug Results in Similar Weight Loss Levels as Novo’s Ozempic

Comparing the Competitors: Pfizer’s Danuglipron vs. Novo Nordisk’s Ozempic

A recent mid-stage study has shown promising weight-loss results for Pfizer’s diabetes drug, danuglipron, drawing an interesting comparison with Novo Nordisk’s Ozempic.

Key Points:

• Pfizer’s diabetes drug, danuglipron, demonstrated weight loss comparable to Novo Nordisk’s Ozempic in a mid-stage study involving type 2 diabetes patients.
• At its highest dose, danuglipron reduced both blood sugar and body weight after 16 weeks compared to a placebo.
• The trial involved 411 adults with type 2 diabetes, some of whom received the drug and others a placebo.
• A 120-milligram dose of danuglipron resulted in an average weight loss of around 4.6 kilograms (approximately 10 pounds) after 16 weeks.
• Pfizer also has another oral diabetes drug, lotiglipron, in the pipeline, which it may bring to late-stage development.

Additional Points:

• The news of the drug’s effectiveness boosted Pfizer’s share value by 4.5%.
• The weight loss treatment market is projected to hit $100 billion by the end of the decade, making it a focus of investor interest.
• Both danuglipron and Ozempic belong to a class of drugs that imitate the gut hormone glucagon-like peptide-1 (GLP-1), designed to suppress appetite and initially developed for type 2 diabetes treatment.
• Pfizer believes that an oral therapy could be more appealing to patients wanting to avoid injections.

Related Link:

• Amid high-profile injectable launch, Novo Nordisk scores with its pill version of obesity drug Wegovy